<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230615058491N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-11-12</date_registration>
      <primary_sponsor>Rehman Medical Institute RMI</primary_sponsor>
      <public_title>Effects of Theraband-assisted training on balance and gait outcomes in stroke patients</public_title>
      <acronym></acronym>
      <scientific_title>The effects of Theraband-assisted treadmill training on balance and gait outcomes in stroke patients: A randomised controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-09-18</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72444</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In our trial, randomization will be conducted using a sealed envolpe method. The unit of randomization is the individual participant. For each participant, a unique identifier will be assigned, and these identifiers will be placed in separate, opaque, and sealed envelopes. The envelopes will be thoroughly mixed before a neutral third party, who is not involved in the trial, draws an envelope for each participant. The treatment assignment corresponding to the label inside the drawn envelope will determine whether the participant receives Theraband-assisted treadmill training or standard treadmill training. This method ensures the transparency and fairness of the allocation process, eliminating any potential for selection bias. Allocation concealment will be maintained throughout the trial, as the envelopes will be securely stored and opened only at the time of participant allocation, Blinding description: One physical therapist will provide the treatment session, another physical therapist will assess the pre and post Tx outcomes of the patients from both groups, outcomes assessor will be blinded in this study.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Stroke.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: •	A total of 50 minutes session will be given which will include Treadmill training with theraband for 30 minutes in a harness support and conventional therapy (general stretching &amp; strengthening exercises) for 20 minutes, 5 days a week for a total of 4 weeks.•	30 minutes treadmill training will be given in three sets each of 10 minutes (8 minutes training with 2 minutes rest in between).•	Participants will walk on treadmill at a normal pace. Speed for the first 2 weeks will be 1m/s and of the last 2 weeks will be 1.5m/s. •	Two theraband will be used, green color theraband will be used to assist dorsiflexion, while the black theraband will be tied to an abdominal belt crossing in front of the ankle, back of the knee and front of the hip joint. Intervention 2: Control group: •	A total of 50 minutes session will be given which will include Treadmill training for 30 minutes in a harness support and conventional therapy (general stretching &amp; strengthening exercises) for 20 minutes, 5 days a week for a total of 4 weeks.•	30 minutes treadmill training will be given in three sets each of 10 minutes (8 minutes training with 2 minutes rest in between).•	Participants will walk on treadmill at a normal pace. Speed for the first 2 weeks will be 1m/s and of the last 2 weeks will be 1.5m/s.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Primary outcomes data

When:
Data will be availabe in January 2024 for two years

To whom:
All the students, teachers and resreach scholars

Conditions:
The person will have to email the principal investigator for data

Where to obtain:
From Prinicapal investigator

How to obtain:
Through mail communication with author

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maaham Ali</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>5-B/2 Shaukat Khanum Rd, Phase 5 Hayatabad, Peshawar, Khyber Pakhtunkhwa</address>
        <city>Peshwar</city>
        <country1>Pakistan</country1>
        <zip>25000</zip>
        <telephone>+92 336 8830999</telephone>
        <email>maahamali99@gmail.com</email>
        <affiliation>Khyber medical university</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maaham Ali</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>5-B/2 Shaukat Khanum Rd, Phase 5 Hayatabad, Peshawar, Khyber Pakhtunkhwa</address>
        <city>Peshawar</city>
        <country1>Pakistan</country1>
        <zip>25000</zip>
        <telephone>+92 336 8830999</telephone>
        <email>maahamali99@gmail.com</email>
        <affiliation>Khyber medical university</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Stroke onset greater than 6 months.
Age between 30-65yrs.
Ability to follow one step command, MMSE scores ≥24.
Ability to walk independently or with assistive device.
Participants who are interested and able to take part in a supervised rehabilitation program for at least 4 weeks.</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>More than one hemisphere involved.
Recurrent strokes greater than two.
Participants with any diagnosed cardiovascular illness or diabetic neuropathy.
Participants with any diagnosed neurological or musculoskeletal problems, other than stroke, that impact their gait or balance.
Participants who currently have or have previously had any diagnosed vestibular problems.
Having any diagnosed significant lower limb abnormalities (e.g. clubfoot, polio, foot drop, fractures).</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G46.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Cerebellar stroke syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: •	A total of 50 minutes session will be given which will include Treadmill training with theraband for 30 minutes in a harness support and conventional therapy (general stretching &amp; strengthening exercises) for 20 minutes, 5 days a week for a total of 4 weeks.•	30 minutes treadmill training will be given in three sets each of 10 minutes (8 minutes training with 2 minutes rest in between).•	Participants will walk on treadmill at a normal pace. Speed for the first 2 weeks will be 1m/s and of the last 2 weeks will be 1.5m/s. •	Two theraband will be used, green color theraband will be used to assist dorsiflexion, while the black theraband will be tied to an abdominal belt crossing in front of the ankle, back of the knee and front of the hip joint.</i_keyword>
      <i_keyword>Control group: •	A total of 50 minutes session will be given which will include Treadmill training for 30 minutes in a harness support and conventional therapy (general stretching &amp; strengthening exercises) for 20 minutes, 5 days a week for a total of 4 weeks.•	30 minutes treadmill training will be given in three sets each of 10 minutes (8 minutes training with 2 minutes rest in between).•	Participants will walk on treadmill at a normal pace. Speed for the first 2 weeks will be 1m/s and of the last 2 weeks will be 1.5m/s.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>GAIT. Timepoint: Before intervention as a baseline and then at the end of intervention after 4 weeks. Method of measurement: 10 meter walk test will be used to assess the GAIT outcome of patient. A stopwatch and a 10 m pathway will be required for  the test. A score of &lt;0.4m/s shows household ambulation, 0.4-0.8m/s shows limited community ambulation and &gt;0.8m/s shows community ambulation.</prim_outcome>
      <prim_outcome>Balance. Timepoint: Before intervention as a baseline and then at the end of intervention after 4 weeks. Method of measurement: Functional reach test will be used to assess the balance of the participants. It will need measuring tape on the wall and patient will lean forward and score will be noted. A score of greater than 25 will be considered low risk, 15-25 moderate risk and less than 15 high risk of fall.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rehman Medical Institute RMI</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-09-04</approval_date>
        <contact_name>KMU AS&amp;RB</contact_name>
        <contact_address>Hayatabad phase 5 Peshawar Khyber pakhtunkhwa Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
